News

Foundations Merge to Do More for People With Lung Diseases

Two Montreal-based foundations are joining forces to boost research and care into complex and chronic respiratory disorders, including chronic obstructive pulmonary disease (COPD). The merging of the McGill University Health Centre (MUHC) Foundation and the Montreal Chest Institute (MCI) Foundation comes as the MUHC opens a $10 million…

Partnership Brings Quantitative Imaging Analysis to Diagnosis, Care

A new collaboration is seeking to bring quantitative imaging analysis to diagnosis and care of patients with chronic lung diseases, including chronic obstructive pulmonary disease (COPD) and emphysema. The agreement is between Spesana, a healthcare platform focused on molecular diagnostics and in building an accessible database for physicians,…

FDA OKs Pivotal Trial Testing RheOx System in Chronic Bronchitis

The U.S. Food and Drug Administration (FDA) has cleared the start of an international pivotal trial to test the RheOx System, Gala Therapeutics’ medical device, in adults with chronic obstructive pulmonary disease (COPD) who have moderate to severe chronic bronchitis. “Chronic bronchitis is a debilitating disease which results…

New Algorithm May Find Misdiagnosis in COPD

A new algorithm-based approach was developed to identify patients at risk of being misdiagnosed with chronic obstructive pulmonary disease (COPD). Researchers believe this may become an important tool to help healthcare providers in diagnosing several diseases. “Our new algorithm can find the patients who have such an unusual disease…

Trixeo Aerosphere Approved in Scotland as COPD Maintenance Therapy

The Scottish Medicines Consortium (SMC) has approved AstraZeneca‘s triple combination therapy Trixeo Aerosphere as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The approval specifically covers adults with moderate to severe disease who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a…

FDA Gives Green Light to Clinical Trial of Zofin

The U.S. Food and Drug Administration (FDA) has granted Organicell Regenerative Medicine permission to begin a clinical trial testing the company’s lead product, Zofin, in people with chronic obstructive pulmonary disease (COPD). The approved trial design will be a double-blinded, placebo-controlled, phase 1/2 trial to assess the…